Malvern, Pa.
Went public 11/14/00 at $15 per share
Filing Range:6.0 million shares @ $15 to $17
Shares Outstanding:26.849 million shares
Underwriters: Merrill Lynch & Co./Lehman Brothers/Pacific Growth Equities Inc.
Company Counsel: Dechert Price & Rhoads
Manager Counsel: Brobeck Phleger & Harrison LLP
Auditor: KPMG LLP
The Company:
Develops biopharmaceuticals, including novel analgesics and products for pain management. The company develops next-generation centrally and peripherally-acting, non-addictive analgesics for the treatment of hyperalgesia (inflammatory pain), pruritis (itch), mild-moderate and moderate-severe pain. The company is also developing products that are designed to greatly diminish most of the prevalent and dose-limiting side effects of current narcotic therapy.
Venture Backers
Lightspeed Venture Partners
ARCH Venture Partners
Sprout Group
MPM Capital
OrbiMed Advisors LLC
Alta Partners
TL Ventures
EuclidSR Partners
OneLiberty Ventures
HarbourVest Partners LLC.
Tredegar Investments
Burr Egan Deleage & Co.
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 11/01/1994 3 Early Stage 1500.0
2 06/01/1996 6 Early Stage 7547.0
3 05/02/1997 9 Expansion 9670.0
4 12/08/1998 9 Later Stage 8525.0
5 01/28/2000 12 Expansion 12300.0
6 07/10/2000 10 Later Stage 35883.0
Financials:
(Data in $ millions)
Y/E
12/31/99
Total Revenues: 0.0
Net Income: -10.1